Folate receptor-targeted liposomes enhanced the antitumor potency of imatinib through the combination of active targeting and molecular targeting

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 2167-2178

  Ye, Peng ^a,b   Zhang, Wendian ^a   Yang, Tan ^a   Lu, Yao ^a   Lu, Miao ^a   Gai, Yongkang ^a   Ma, Xiang ^a   Xiang, Guangya ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Folate receptor; Imatinib; Liposomes; PDGFR; Tumor targeting

Indexed keywords

FOLATE RECEPTOR; IMATINIB; LIPOSOME; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; FOLIC ACID; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG CLEARANCE; DRUG FORMULATION; DRUG HALF LIFE; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RELEASE; DRUG RETENTION; DRUG STABILITY; DRUG TARGETING; DRUG UPTAKE; FEMALE; HELA CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL DELIVERY; MOUSE; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PH; TRANSMISSION ELECTRON MICROSCOPY; ZETA POTENTIAL; CELL SURVIVAL; CHEMISTRY; DIFFUSION; DRUG EFFECTS; DRUG POTENTIATION; METABOLISM; MOLECULARLY TARGETED THERAPY; MULTIMODALITY CANCER THERAPY; NEOPLASMS, EXPERIMENTAL; PROCEDURES; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; BENZAMIDES; CELL SURVIVAL; COMBINED MODALITY THERAPY; DIFFUSION; DRUG SYNERGISM; FOLATE RECEPTORS, GPI-ANCHORED; FOLIC ACID; HELA CELLS; HUMANS; LIPOSOMES; MOLECULAR TARGETED THERAPY; NEOPLASMS, EXPERIMENTAL; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 84900433657     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S60178     Document Type: Article

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Kong TW, Chang SJ, Paek J, et al. Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer. J Gynecol Oncol. 2012;23(4):235-241.
3. Rose PG. Chemoradiotherapy for cervical cancer. Eur J Cancer. 2002;38(2):270-278.
4. Steinert DM, McAuliffe JC, Trent JC. Imatinib mesylate in the treatment of gastrointestinal stromal tumour. Expert Opin Pharmacother. 2005;6(1):105-113.
5. Savage DG, Antman KH. Imatinib mesylate - a new oral targeted therapy. N Engl J Med. 2002;346(9):683-693.
6. Capdeville R, Buchdunger E, Zimmermann J, Matter A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov. 2002;1(7):493-502.
7. Buchdunger E, O'Reilly T, Wood J. Pharmacology of imatinib (STI571). Eur J Cancer. 2002;38 Suppl 5:S28-S36.
8. Östman A, Heldin CH. PDGF receptors as targets in tumor treatment. 2007;97:247-274.
9. Taja-Chayeb L, Chavez-Blanco A, Martinez-Tlahuel J, et al. Expression of platelet derived growth factor family members and the potential role of imatinib mesylate for cervical cancer. Cancer Cell Int. 2006;6:22.
10. Mayer TJ, Frauenhoffer EE, Meyers AC. Expression of epidermal growth factor and platelet-derived growth factor receptors during cervical carcinogenesis. In Vitro Cell Dev Biol Anim. 2000;36(10):667-676.
11. Kummel S, Heidecke H, Brock B, et al. [Imatinib - a possible therapeutic option for cervical carcinoma: results of a preclinical phase I study]. Gynakol Geburtshilfliche Rundsch. 2008;48(2):94-100. German.
12. Candelaria M, Arias-Bonfill D, Chavez-Blanco A, et al. Lack in efficacy for imatinib mesylate as second-line treatment of recurrent or metastatic cervical cancer expressing platelet-derived growth factor receptor alpha. Int J Gynecol Cancer. 2009;19(9):1632-1637.
13. Rao K, Goodin S, Levitt MJ, et al. A phase II trial of imatinib mesylate in patients with prostate specific antigen progression after local therapy for prostate cancer. Prostate. 2005;62(2):115-122.
14. Alberts DS, Liu PY, Wilczynski SP, et al. Phase II trial of imatinib mesylate in recurrent, biomarker positive, ovarian cancer (Southwest Oncology Group Protocol S0211). Int J Gynecol Cancer. 2007;17(4):784-788.
15. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031-1037.
16. Kubler HR, van Randenborgh H, Treiber U, et al. In vitro cytotoxic effects of imatinib in combination with anticancer drugs in human prostate cancer cell lines. Prostate. 2005;63(4):385-394.
17. Mundhenke C, Weigel MT, Sturner KH, et al. Novel treatment of ovarian cancer cell lines with Imatinib mesylate combined with Paclitaxel and Carboplatin leads to receptor-mediated antiproliferative effects. J Cancer Res Clin Oncol. 2008;134(12):1397-1405.
18. Gambacorti-Passerini C, Zucchetti M, Russo D, et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res. 2003;9(2):625-632.
19. Slingerland M, GucHeLaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. 2012;17(3-4):160-166.
20. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297-315.
21. Wang X, Yang L, Chen ZG, Shin DM. Application of nanotechnology in cancer therapy and imaging. CA Cancer J Clin. 2008;58(2):97-110.
22. Barenholz Y. Doxil® - the first FDA-approved nano-drug: lessons learned. J Control Release. 2012;160(2):117-134.
23. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818-1822.
24. Chen X, Wang X, Wang Y, et al. Improved tumor-targeting drug delivery and therapeutic efficacy by cationic liposome modified with truncated bFGF peptide. J Control Release. 2010;145(1):17-25.
25. Mamot C, Drummond DC, Noble CO, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65(24): 11631-11638.
26. Chaudhury A, Tan BJ, Das S, Chiu GN. Increased ERK activation and cellular drug accumulation in the enhanced cytotoxicity of folate receptor-targeted liposomal carboplatin. Int J Oncol. 2012;40(3): 703-710.
27. Watanabe K, Kaneko M, Maitani Y. Functional coating of liposomes using a folate-polymer conjugate to target folate receptors. Int J Nanomedicine. 2012;7:3679-3688.
28. Liu Y, Xu S, Teng L, et al. Synthesis and evaluation of a novel lipophilic folate receptor targeting ligand. Anticancer Res. 2011;31(5):1521-1525.
29. Xiong S, Yu B, Wu J, Li H, Lee RJ. Preparation, therapeutic efficacy and intratumoral localization of targeted daunorubicin liposomes conjugating folate-PEG-CHEMS. Biomed Pharmacother. 2011;65(1):2-8.
30. Hilgenbrink AR, Low PS. Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci. 2005;94(10):2135-2146.
31. Lu Y, Ding N, Yang C, Huang L, Liu J, Xiang G. Preparation and in vitro evaluation of a folate-linked liposomal curcumin formulation. J Liposome Res. 2012;22(2):110-119.
32. Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev. 2004;56(8):1099-1109.
33. Liu YF, Wang CL, Bai YJ, Han N, Jiao JP, Qi XL. A facile total synthesis of imatinib base and its analogues. Org Process Res Dev. 2008;12(3):490-495.
34. Xiang G, Wu J, Lu Y, Liu Z, Lee RJ. Synthesis and evaluation of a novel ligand for folate-mediated targeting liposomes. Int J Pharm. 2008;356(1-2):29-36.
35. Haran G, Cohen R, Bar LK, Barenholz Y. Transmembrane ammonium sulfate gradients in liposomes produce efficient and stable entrapment of amphipathic weak bases. Biochim Biophys Acta. 1993;1151(2):201-215.
36. Hinrichs WL, Mancenido FA, Sanders NN, et al. The choice of a suitable oligosaccharide to prevent aggregation of PEGylated nanoparticles during freeze thawing and freeze drying. Int J Pharm. 2006;311(1-2):237-244.
37. Zhang P, Gao WY, Turner S, Ducatman BS. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro. Mol Cancer. 2003;2:1.
38. Ehnman M, Östman A. Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. Exp Opin Invest Drug. 2014;23(2):211-226.
39. Mendonca LS, Moreira JN, de Lima MC, Simoes S. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng. 2010;107(5):884-893.
40. Harata M, Soda Y, Tani K, et al. CD19-targeting liposomes containing imatinib efficiently kill Philadelphia chromosome-positive acute lymphoblastic leukemia cells. Blood. 2004;104(5):1442-1449.
41. Beni S, Budai M, Noszal B, Grof P. Molecular interactions in imatinib-DPPC liposomes. Eur J Pharm Sci. 2006;27(2-3):205-211.
42. Mattheolabakis G, Rigas B, Constantinides PP. Nanodelivery strategies in cancer chemotherapy: biological rationale and pharmaceutical perspectives. Nanomedicine (Lond). 2012;7(10):1577-1590.
43. Riaz M. Review article: stability and uses of liposomes. Pak J Pharm Sci. 1995;8(2):69-79.
44. Lee RJ, Wang S, Turk MJ, Low PS. The effects of pH and intraliposomal buffer strength on the rate of liposome content release and intracellular drug delivery. Biosci Rep. 1998;18(2):69-78.
45. Karve S, Bajagur Kempegowda G, Sofou S. Heterogeneous domains and membrane permeability in phosphatidylcholine-phosphatidic acid rigid vesicles as a function of pH and lipid chain mismatch. Langmuir. 2008;24(11):5679-5688.
46. Xiong XB, Huang Y, Lu WL, et al. Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release. 2005;107(2):262-275.